KDS2010

NeuroBiogen Co., Ltd · Phase 2 active Small molecule

At a glance

Generic name	KDS2010
Sponsor	NeuroBiogen Co., Ltd
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease (PHASE2)
Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KDS2010 CI brief — competitive landscape report
KDS2010 updates RSS · CI watch RSS
NeuroBiogen Co., Ltd portfolio CI